Search

Changes to Formulary as of 25th March 2021:

BNF Category Number

Product/indication

Detail of change

Various

Various

All NOT APPROVED/Grey Drugs – wording as to reason for status added from DNP/Grey List

4.1.1

Melatonin (Slentyo®)

Changed from under review to AMBER SC

5.1.10

Dapsone for dermatology use

Changed from AMBER SI to AMBER SC

6.6.1

Teriparatide

Added as approved for use in men as per NHSE commissioning policy

18

Phenol in Glycerol 5%

Added as a RED drug

5.3.1

Juluca®

Added as a RED drug

5.3.1

Dovato®

Added as a RED drug

5.1.2.3

Nebulised aztreonam

Added as a RED drug

5.1.4

Aminoglycosides (gentamicin, amikacin, tobramycin, and neomycin): increased risk of deafness in patients with mitochondrial mutations

Added link to MHRA Drug Safety Update

5.3

SSRI/SNRI antidepressant medicines: small increased risk of postpartum haemorrhage when used in the month before delivery

Added link to MHRA Drug Safety Update

8.2.4

Fingolimod (Gilenya▼): updated advice about the risks of serious liver injury and herpes meningoencephalitis

Added link to MHRA Drug Safety Update

8.2.4

Dimethyl fumarate (Tecfidera): updated advice on the risk of progressive multifocal leukoencephalopathy (PML) associated with mild lymphopenia

Added link to MHRA Drug Safety Update

14.4

COVID-19 vaccines (Pfizer/BioNTech and COVID-19 Vaccine AstraZeneca): current advice

Added link to MHRA Drug Safety Update

4.8

Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review

 

Added link to MHRA Drug Safety Update

5.1.5

Erythromycin: update on known risk of infantile hypertrophic pyloric stenosis

Added link to MHRA Drug Safety Update

5.1.5

Erythromycin: caution required due to cardiac risks (QT interval prolongation); drug interaction with rivaroxaban

Added link to MHRA Drug Safety Update

5.1

Systemic and inhaled fluoroquinolones: small risk of heart valve regurgitation; consider other therapeutic options first in patients at risk

Added link to MHRA Drug Safety Update

4.4

Solriamfetol for nacrolepsy

Added as a RED drug and added link to NTAG recommendation

4.4

Solrimamfetol for obstructive sleep apnoea

Added as NOT APPROVED drug and added link to NTAG recommendation

9

 

Added link to NICE NG187

8.1.5

Brigatinib

Added link to NICE TA670

8.1.5

Trifluridine-tipiracil

Added link to NICE TA669

8.1.5

Encorafenib

Added link to NICE TA668

8.2.3

Caplacizumab

Added as a RED drug and added link to NICE TA667

8.2.4

Atezolizumab

Added link to NICE TA666

10.1.3

Upadacitinib

Added as a RED drug and added link to NICE TA665

4.5

Liraglutide for obesity

Changed from NOT APPROVED to a RED drug and added link to NICE TA664.

8.1.5

Venetoclax

Added link to NICE TA663